NOVACYT (ALNOV.PA) Fundamental Analysis & Valuation
EPA:ALNOV • FR0010397232
Current stock price
0.375 EUR
+0 (+0.13%)
Last:
This ALNOV.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ALNOV.PA Profitability Analysis
1.1 Basic Checks
- In the past year ALNOV has reported negative net income.
- ALNOV had a negative operating cash flow in the past year.
- In the past 5 years ALNOV reported 4 times negative net income.
- The reported operating cash flow has been mixed in the past 5 years: ALNOV reported negative operating cash flow in multiple years.
1.2 Ratios
- With a Return On Assets value of -48.32%, ALNOV is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
- ALNOV has a Return On Equity of -74.44%. This is comparable to the rest of the industry: ALNOV outperforms 47.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.32% | ||
| ROE | -74.44% | ||
| ROIC | N/A |
ROA(3y)-32.84%
ROA(5y)-9.46%
ROE(3y)-47.33%
ROE(5y)-12.19%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ALNOV has a Gross Margin of 63.35%. This is comparable to the rest of the industry: ALNOV outperforms 53.57% of its industry peers.
- ALNOV's Gross Margin has improved in the last couple of years.
- ALNOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y75.01%
GM growth 5Y20.62%
2. ALNOV.PA Health Analysis
2.1 Basic Checks
- ALNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
- ALNOV has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for ALNOV has been increased compared to 5 years ago.
- Compared to 1 year ago, ALNOV has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 0.44, we must say that ALNOV is in the distress zone and has some risk of bankruptcy.
- ALNOV has a Altman-Z score (0.44) which is in line with its industry peers.
- A Debt/Equity ratio of 0.24 indicates that ALNOV is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.24, ALNOV is in line with its industry, outperforming 58.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.44 |
ROIC/WACCN/A
WACC6.62%
2.3 Liquidity
- A Current Ratio of 5.03 indicates that ALNOV has no problem at all paying its short term obligations.
- With a decent Current ratio value of 5.03, ALNOV is doing good in the industry, outperforming 79.76% of the companies in the same industry.
- A Quick Ratio of 4.59 indicates that ALNOV has no problem at all paying its short term obligations.
- ALNOV's Quick ratio of 4.59 is fine compared to the rest of the industry. ALNOV outperforms 79.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.03 | ||
| Quick Ratio | 4.59 |
3. ALNOV.PA Growth Analysis
3.1 Past
- ALNOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.85%, which is quite good.
- The Revenue has grown by 8.50% in the past year. This is quite good.
- Measured over the past years, ALNOV shows a quite strong growth in Revenue. The Revenue has been growing by 11.35% on average per year.
EPS 1Y (TTM)17.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.73%
Revenue 1Y (TTM)8.5%
Revenue growth 3Y-40.37%
Revenue growth 5Y11.35%
Sales Q2Q%-5.12%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. ALNOV.PA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ALNOV. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. ALNOV.PA Dividend Analysis
5.1 Amount
- No dividends for ALNOV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ALNOV.PA Fundamentals: All Metrics, Ratios and Statistics
EPA:ALNOV (4/13/2026, 7:00:00 PM)
0.375
+0 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)04-30 2026-04-30
Inst Owners0.05%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap27.22M
Revenue(TTM)19.10M
Net Income(TTM)-30.40M
Analysts37.14
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.24 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.58 | ||
| P/tB | 1.09 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.5
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.3
BVpS0.65
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.32% | ||
| ROE | -74.44% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.35% | ||
| FCFM | N/A |
ROA(3y)-32.84%
ROA(5y)-9.46%
ROE(3y)-47.33%
ROE(5y)-12.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y75.01%
GM growth 5Y20.62%
F-Score4
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 8.2% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.03 | ||
| Quick Ratio | 4.59 | ||
| Altman-Z | 0.44 |
F-Score4
WACC6.62%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.93%
Cap/Sales(5y)4.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.5%
Revenue growth 3Y-40.37%
Revenue growth 5Y11.35%
Sales Q2Q%-5.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.03%
OCF growth 3YN/A
OCF growth 5YN/A
NOVACYT / ALNOV.PA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of NOVACYT (ALNOV.PA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ALNOV.PA.
What is the valuation status of NOVACYT (ALNOV.PA) stock?
ChartMill assigns a valuation rating of 0 / 10 to NOVACYT (ALNOV.PA). This can be considered as Overvalued.
What is the profitability of ALNOV stock?
NOVACYT (ALNOV.PA) has a profitability rating of 1 / 10.